Biologics News
INQOVI (cedazuridine and decitabine), FDA Approved for Treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, Available at Biologics by McKesson
CARY, N.C., August 21, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Taiho Oncology, Inc. as a specialty pharmacy provider for INQOVI® (decitabine and cedazuridine) tablets for the...
A Letter to Our Customers from Our New General Manager, Brandon Tom
Valued Customers, As the new vice president and general manager of Biologics by McKesson, let me start by saying I am truly thrilled to lead this wonderful company and the amazing people who provide our services to you and your patients every day. I am also equally...
XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL), Available at Biologics by McKesson
CARY, N.C., June 29, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology, rare diseases and other complex therapeutic areas, was selected by Karyopharm Therapeutics, Inc. as a specialty pharmacy provider for XPOVIO® (selinexor) for...
Brandon Tom Appointed New General Manager of Biologics by McKesson
CARY, N.C., June 22, 2020—Biologics by McKesson, an independent specialty pharmacy and patient services company specializing in oncology, rare diseases and other complex therapeutic areas, is pleased to announce that Brandon Tom, PharmD, was named its new general...
QINLOCK (Ripretinib), FDA Approved for Treatment of Gastrointestinal Stromal Tumors (GIST), Available at Biologics by McKesson
CARY, N.C., June 2, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Deciphera Pharmaceuticals as a specialty pharmacy provider for QINLOCK™ (ripretinib) for the treatment of adult patients...
RETEVMO (selpercatinib), FDA-Approved for Treatment of RET-driven Lung and Thyroid Cancers, Available at Biologics by McKesson
CARY, N.C., June 1—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Eli Lilly and Company as a specialty pharmacy provider for RETEVMO™ (selpercatinib), the first drug approved by the U.S....
Pemazyre™ (pemigatinib) Available Exclusively at Biologics by McKesson
CARY, N.C., May 27, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, will be the exclusive specialty pharmacy provider for Pemazyre™ (pemigatinib), Incyte’s selective fibroblast growth factor receptor...
TRODELVY (sacituzumab govitecan-hziy), FDA Approved for Treatment of Metastatic Triple-negative Breast Cancer, Available Only at Biologics by McKesson
CARY, N.C., May 8, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Immunomedics, Inc. as a specialty pharmacy provider for TRODELVY™ (sacituzumab govitecan-hziy) for the treatment of...
TUKYSA (tucatinib), FDA Approved for Treatment of Advanced Unresectable or Metastatic HER2 Positive Breast Cancer, Available at Biologics by McKesson
CARY, N.C., April 17, 2020—Biologics by McKesson, an independent specialty pharmacy for oncology and other rare and complex therapeutic areas, has been selected by Seattle Genetics as a specialty pharmacy provider for TUKYSA™ (tucatinib) for the treatment of HER2...
DOPTELET (avatrombopag) Now Available at Biologics by McKesson
Biologics selected for distribution network based on its expertise in high-touch support for oncology and complex disease patients CARY, N.C., March 17, 2020—Biologics by McKesson, an independent specialty pharmacy for oncology and complex care, was selected by AkaRx,...